Safety and Effectiveness of a Biosimilar Recombinant Human Growth Hormone in Children Requiring Growth Hormone Treatment: Analysis of Final Data from PATRO Children, an International, Post-Marketing Surveillance Study.
Sandro LocheShankar KanumakalaPhilippe F BackeljauwKarl Otfried SchwabAlfonso María Lechuga-SanchoAltaher EsmaelDragan UrosevicAnca BoldeaMarkus ZabranskyPublished in: Drug design, development and therapy (2024)
This final analysis of the PATRO Children study indicates that biosimilar rhGH is well tolerated and effective in real-world clinical practice. These data are consistent with the well-characterized safety profile of rhGH treatment in pediatric patients.